Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.1%

5 terminated/withdrawn out of 62 trials

Success Rate

88.9%

+2.3% vs industry average

Late-Stage Pipeline

27%

17 trials in Phase 3/4

Results Transparency

40%

16 of 40 completed trials have results

Key Signals

6 recruiting16 with results5 withdrawn

Enrollment Performance

Analytics

Phase 2

12(28.6%)

Phase 1

11(26.2%)

Phase 4

10(23.8%)

Phase 3

7(16.7%)

Early Phase 1

1(2.4%)

N/A

1(2.4%)

42Total

Phase 2(12)

Phase 1(11)

Phase 4(10)

Phase 3(7)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (62)

Showing 20 of 62 trials

NCT07831824Phase 2Recruiting

Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])

Role: lead

NCT05712473Active Not Recruiting

An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

Role: lead

NCT05394259Phase 1Active Not Recruiting

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Role: collaborator

NCT07645326Phase 2Not Yet Recruiting

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Role: collaborator

NCT07357519Phase 1Recruiting

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Role: lead

NCT03674255Enrolling By Invitation

Echocardiography: Value and Accuracy at REst and STress

Role: collaborator

NCT07501650Phase 1Recruiting

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Role: collaborator

NCT05160480Enrolling By Invitation

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Role: collaborator

NCT03493516Active Not Recruiting

Prediction of ARrhythmic Events With Positron Emission Tomography II

Role: collaborator

NCT07335315Recruiting

Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

Role: collaborator

NCT07084909Phase 2Withdrawn

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

Role: lead

NCT06074510Phase 4Active Not Recruiting

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

Role: lead

NCT06361810Phase 1Withdrawn

PSMA Therapy and Immunotherapy in Kidney Cancer

Role: collaborator

NCT06298916Phase 1Recruiting

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer